Skip to main content
SpringerLink
Log in

Combined Fascin-1 and MAP17 Expression in Breast Cancer Identifies Patients with High Risk for Disease Recurrence

  • Original Research Article
  • Published:
Molecular Diagnosis & Therapy Aims and scope Submit manuscript

Abstract

Background and Objective

Breast cancer stem cells are considered to be a major cause of disease recurrence in breast cancer as they appear to be chemoresistant. Fascin-1 and MAP17 are stem cell markers whose excessive expression in tumors is associated with aggressive tumor phenotypes. The aim of the present study was to investigate the expression patterns of fascin-1 and MAP17 in breast cancer and to assess their clinical significance.

Methods

Expression of fascin-1 and MAP17 was assessed via immunohistochemistry in surgical specimens of a cohort comprised of 127 patients with resectable breast cancer. Results were correlated with clinicopathological characteristics and survival data. Progression-free survival (PFS) was defined as the primary outcome of the present study.

Results

Fascin-1 and MAP17 expression were strongly associated with the presence of triple-negative cancers (p < 0.0001). Tumors displaying high expression of fascin-1 presented correlations with high tumor grade (p = 0.002) and high expression of Ki-67 (p = 0.004). PFS of patients exhibiting high expression of fascin-1 and MAP17 in cancer cells in the first 5 years after surgery was significantly worse than in patients with low expression of the two markers (47.8%, 95% confidence interval [CI] 33–51 vs. 80.5%, 95% CI 47–56; p = 0.012) and independent of other clinicopathological characteristics (hazard ratio 0.171, 95% CI 0.034–0.869; p = 0.033).

Conclusion

Combined expression of fascin-1 and MAP17 in breast cancer cells is associated with a significantly worse 5-year PFS, therefore recognizing a group of patients with high risk for early disease recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.

    Article  PubMed  Google Scholar 

  2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.

  3. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14(10):2738–46.

    Article  CAS  PubMed  Google Scholar 

  4. Richman J, Dowsett M. Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer. Nat Rev Clin Oncol. 2019;16(5):296–311. https://doi.org/10.1038/s41571-018-0145-5.

    Article  CAS  PubMed  Google Scholar 

  5. Jiang Y, Wells A, Sylakowski K, Clark AM, Ma B. Adult stem cell functioning in the tumor micro-environment. Int J Mol Sci. 2019;20(10):2566. https://doi.org/10.3390/ijms20102566.

    Article  PubMed Central  Google Scholar 

  6. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9(4):265–73.

    Article  CAS  PubMed  Google Scholar 

  7. Grimshaw MJ, Cooper L, Papazisis K, Coleman JA, Bohnenkamp HR, Chiapero-Stanke L, et al. Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res. 2008;10(3):R52.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Marotta LL, Polyak K. Cancer stem cells: a model in the making. Curr Opin Genet Dev. 2009;19(1):44–50.

    Article  PubMed  Google Scholar 

  9. Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science. 2009;324(5935):1670–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 2009;138(5):822–9.

    Article  CAS  PubMed  Google Scholar 

  11. Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci USA. 2011;108(4):1397–402.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Gloushankova NA, Zhitnyak IY, Rubtsova SN. Role of epithelial-mesenchymal transition in tumour progression. Biochemistry (Mosc). 2018;83(12):1469–76. https://doi.org/10.1134/S0006297918120052.

    Article  CAS  Google Scholar 

  13. Huang FK, Han S, Xing B, Huang J, Liu B, Bordeleau F, et al. Targeted inhibition of fascin function blocks tumour invasion and metastatic colonization. Nat Commun. 2015;17(6):7465. https://doi.org/10.1038/ncomms8465.

    Article  CAS  Google Scholar 

  14. Mattila PK, Lappalainen P. Filopodia: molecular architecture and cellular functions. Nat Rev Mol Cell Biol. 2008;9(6):446–54.

    Article  CAS  PubMed  Google Scholar 

  15. Claessens MM, Bathe M, Frey E, Bausch AR. Actin-binding proteins sensitively mediate F-actin bundle stiffness. Nat Mater. 2006;5(9):748–53.

    Article  CAS  PubMed  Google Scholar 

  16. Lee HJ, An HJ, Kim TH, Kim G, Kang H, Heo JH, et al. Fascin expression is inversely correlated with breast cancer metastasis suppressor 1 and predicts a worse survival outcome in node-negative breast cancer patients. J Cancer. 2017;8(16):3122–9. https://doi.org/10.7150/jca.22046 (eCollection 2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Jayo A, Malboubi M, Antoku S, Chang W, Ortiz-Zapater E, Groen C, et al. Fascin regulates nuclear movement and deformation in migrating cells. Dev Cell. 2016;38(4):371–83. https://doi.org/10.1016/j.devcel.2016.07.021.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Hashimoto Y, Kim DJ, Adams JC. The roles of fascins in health and disease. J Pathol. 2011;224(3):289–300.

    Article  CAS  PubMed  Google Scholar 

  19. Machesky LM, Li A. Fascin: invasive filopodia promoting metastasis. Commun Integr Biol. 2010;3(3):263–70.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Barnawi R, Al-Khaldi S, Majed Sleiman G, Sarkar A, Al-Dhfyan A, Al-Mohanna F, et al. Fascin is critical for the maintenance of breast cancer stem cell pool predominantly via the activation of the Notch self-renewal pathway. Stem Cells. 2016;34(12):2799–813.

    Article  CAS  PubMed  Google Scholar 

  21. Guijarro MV, Link W, Rosado A, Leal JF, Carnero A. MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation. Carcinogenesis. 2007;28(12):2443–50.

    Article  CAS  PubMed  Google Scholar 

  22. Guijarro MV, Leal JF, Blanco-Aparicio C, Alonso S, Fominaya J, Lleonart M, et al. MAP17 enhances the malignant behavior of tumor cells through ROS increase. Carcinogenesis. 2007;28(10):2096–104.

    Article  CAS  PubMed  Google Scholar 

  23. Chen X, Liao Y, Yu Y, Zhu P, Li J, Qin L, et al. Elevation of MAP17 enhances the malignant behavior of cells via the Akt/mTOR pathway in hepatocellular carcinoma. Oncotarget. 2017;8(54):92589–603.

    PubMed  PubMed Central  Google Scholar 

  24. Perez M, Peinado-Serrano J, Garcia-Heredia JM, Felipe-Abrio I, Tous C, Ferrer I, et al. Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1). Oncotarget. 2016;7(41):67033–46.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Guijarro MV, Leal JF, Fominaya J, Blanco-Aparicio C, Alonso S, Lleonart M, et al. MAP17 overexpression is a common characteristic of carcinomas. Carcinogenesis. 2007;28(8):1646–52.

    Article  CAS  PubMed  Google Scholar 

  26. Carnero A. MAP17 and the double-edged sword of ROS. Biochim Biophys Acta. 2012;1826(1):44–52.

    CAS  PubMed  Google Scholar 

  27. Perez M, Praena-Fernandez JM, Felipe-Abrio B, Lopez-Garcia MA, Lucena-Cacace A, Garcia A, et al. MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival. PLoS One. 2013;8(2):e56169.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol. 2005;2(8):416–22.

    Article  CAS  PubMed  Google Scholar 

  29. Gilliland FD, Joste N, Stauber PM, Hunt WC, Rosenberg R, Redlich G, et al. Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst. 2000;92(9):743–9.

    Article  CAS  PubMed  Google Scholar 

  30. Wang CQ, Li Y, Huang BF, Zhao YM, Yuan H, Guo D, et al. EGFR conjunct FSCN1 as a novel therapeutic strategy in triple-negative breast cancer. Sci Rep. 2017;7(1):15654.

    Article  PubMed  PubMed Central  Google Scholar 

  31. van Cruijsen H, Giaccone G, Hoekman K. Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies. Int J Cancer. 2005;117(6):883–8.

    Article  PubMed  Google Scholar 

  32. Yoder BJ, Tso E, Skacel M, Pettay J, Tarr S, Budd T, et al. The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. Clin Cancer Res. 2005;11(1):186–92.

    CAS  PubMed  Google Scholar 

  33. Grothey A, Hashizume R, Sahin AA, McCrea PD. Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. Br J Cancer. 2000;83(7):870–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Esnakula AK, Ricks-Santi L, Kwagyan J, Kanaan YM, DeWitty RL, Wilson LL, et al. Strong association of fascin expression with triple negative breast cancer and basal-like phenotype in African-American women. J Clin Pathol. 2014;67(2):153–60.

    Article  PubMed  Google Scholar 

  35. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  PubMed  Google Scholar 

  36. Wang CQ, Tang CH, Wang Y, Jin L, Wang Q, Li X, et al. FSCN1 gene polymorphisms: biomarkers for the development and progression of breast cancer. Sci Rep. 2017;7(1):15887.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Jayo A, Parsons M. Fascin: a key regulator of cytoskeletal dynamics. Int J Biochem Cell Biol. 2010;42(10):1614–7.

    Article  CAS  PubMed  Google Scholar 

  38. Li A, Dawson JC, Forero-Vargas M, Spence HJ, Yu X, Konig I, et al. The actin-bundling protein fascin stabilizes actin in invadopodia and potentiates protrusive invasion. Curr Biol. 2010;20(4):339–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Hashimoto Y, Skacel M, Adams JC. Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? Int J Biochem Cell Biol. 2005;37(9):1787–804.

    Article  CAS  PubMed  Google Scholar 

  40. Al-Alwan M, Olabi S, Ghebeh H, Barhoush E, Tulbah A, Al-Tweigeri T, et al. Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules. PLoS One. 2011;6(11):e27339.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Ghebeh H, Al-Khaldi S, Olabi S, Al-Dhfyan A, Al-Mohanna F, Barnawi R, et al. Fascin is involved in the chemotherapeutic resistance of breast cancer cells predominantly via the PI3K/Akt pathway. Br J Cancer. 2014;111(8):1552–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Yao J, Qian CJ, Ye B, Zhao ZQ, Wei J, Liang Y, et al. Signal transducer and activator of transcription 3 signaling upregulates fascin via nuclear factor-kappaB in gastric cancer: Implications in cell invasion and migration. Oncol Lett. 2014;7(3):902–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Guijarro MV, Vergel M, Marin JJ, Munoz-Galvan S, Ferrer I, Ramon y Cajal S, et al. p38alpha limits the contribution of MAP17 to cancer progression in breast tumors. Oncogene. 2012;31(41):4447–59.

    Article  CAS  PubMed  Google Scholar 

  44. Garcia-Heredia JM, Lucena-Cacace A, Verdugo-Sivianes EM, Perez M, Carnero A. The cargo protein MAP17 (PDZK1IP1) regulates the cancer stem cell pool activating the Notch pathway by abducting NUMB. Clin Cancer Res. 2017;23(14):3871–83.

    Article  CAS  PubMed  Google Scholar 

  45. Zhang Y, Li B, Ji ZZ, Zheng PS. Notch1 regulates the growth of human colon cancers. Cancer. 2010;116(22):5207–18.

    Article  CAS  PubMed  Google Scholar 

  46. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer. 2011;11(5):338–51.

    Article  CAS  PubMed  Google Scholar 

  48. Rodriguez-Rodero S, Fernandez AF, Fernandez-Morera JL, Castro-Santos P, Bayon GF, Ferrero C, et al. DNA methylation signatures identify biologically distinct thyroid cancer subtypes. J Clin Endocrinol Metab. 2013;98(7):2811–21.

    Article  CAS  PubMed  Google Scholar 

  49. Garcia-Heredia JM, Carnero A. The cargo protein MAP17 (PDZK1IP1) regulates the immune microenvironment. Oncotarget. 2017;8(58):98580–97.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Guijarro MV, Castro ME, Romero L, Moneo V, Carnero A. Large scale genetic screen identifies MAP17 as protein bypassing TNF-induced growth arrest. J Cell Biochem. 2007;101(1):112–21.

    Article  CAS  PubMed  Google Scholar 

  51. Munoz-Galvan S, Gutierrez G, Perez M, Carnero A. MAP17 (PDZKIP1) expression determines sensitivity to the proteasomal inhibitor bortezomib by preventing cytoprotective autophagy and NFkappaB activation in breast cancer. Mol Cancer Ther. 2015;14(6):1454–65.

    Article  CAS  PubMed  Google Scholar 

  52. Shao Y, Lv H, Zhong DS, Zhou QH. EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties. Oncol Lett. 2018;15(5):6655–65.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. Ekaterini Christina Tampaki and Athanasios Tampakis have contributed equally to this work and therefore share the authorship.

Authors and Affiliations

  1. 2nd Department of Propedeutic Surgery, Athens University Medical School, Laiko General Hospital, 17 Agiou Thoma Street, 11527, Athens, Greece

    Ekaterini Christina Tampaki, Athanasios Tampakis, Konstantinos Kontzoglou & Gregory Kouraklis

  2. Clarunis, University Center for Gastrointestinal and Liver Disorders, University Hospital of Basel, Spitalstraße 21, 4031, Basel, Switzerland

    Athanasios Tampakis & Markus von Flüe

  3. 1st Department of Pathology, School of Medicine, National University of Athens, Athens, Greece

    Afroditi Nonni & Efstratios Patsouris

Authors
  1. Ekaterini Christina Tampaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Athanasios Tampakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Afroditi Nonni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Markus von Flüe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Efstratios Patsouris
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Konstantinos Kontzoglou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gregory Kouraklis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Athanasios Tampakis.

Ethics declarations

Conflict of interest

ECT, AT, AN, MvF, EP, KK, and GK declare no conflict of interest relating to the content of this study.

Funding

No funding was associated with the present study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tampaki, E.C., Tampakis, A., Nonni, A. et al. Combined Fascin-1 and MAP17 Expression in Breast Cancer Identifies Patients with High Risk for Disease Recurrence. Mol Diagn Ther 23, 635–644 (2019). https://doi.org/10.1007/s40291-019-00411-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40291-019-00411-3

Search

Navigation